Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 901–1,000 of 1,000
Willis, G. L., & Armstrong, S. M. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00013-7 · Cited by 15
Nobe, K., Aizawa, H., Ohata, H., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00184-2 · Cited by 14
Pizarro-Galleguillos, B., Kunert, L., Brüggemann, N., & Prasuhn, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213678 · Cited by 13
Medina-Luque, J., Piechocinski, P., Feyen, P., Sgobio, C., & Herms, J. W. (2024) · Scientific Reports · doi:10.1038/s41598-023-49600-5 · Cited by 16
Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology
Currim, F., Tanwar, R., Brown-Leung, J. M., Paranjape, N., Liu, J., Sanders, L. H., Doorn, J. A., & Cannon, J. R. (2024) · NeuroToxicology · doi:10.1016/j.neuro.2024.06.016 · Cited by 15
NiO Nanoparticles Based Carbon Paste as a Sensor for Detection of Dopamine
Reddy, S., Swamy, B. E. K., Ramakrishana, S., He, L., & Jayadevappa, H. P. (2018) · International Journal of Electrochemical Science · doi:10.20964/2018.06.06 · Cited by 14
Exercise-Boosted Mitochondrial Remodeling in Parkinson’s Disease
Magaña, J. C., Deus, C. M., Giné‐Garriga, M., Montané, J., & Pereira, S. P. (2022) · Biomedicines · doi:10.3390/biomedicines10123228 · Cited by 15
“Taking into account the selective degeneration of dopaminergic neurons of SNpc, dopamine itself may be an oxidative stress source inducing alteration in brain homeostasis [49,50].”
BackgroundSubstantia nigra hyperechogenicity is a risk marker of Parkinson’s disease: no
Walter, U. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0564-7 · Cited by 13
“This has been shown by postmortem neuropathological studies in PD patients already in the 1930s and by the discovery, in the 1960s, of the dopaminergic nature of the nigrostriatal neurons that degenerate in PD (Bernheimer et al. 1973; Birkmayer and Hornykiewicz 1962; Hirsch et al. 1988; Parent and Parent 2010; Riedere…”
BackgroundDepboylu, C., Maurer, L., Matusch, A., Hermanns, G., Windolph, A., Béhé, M. P., Oertel, W. H., & Höglinger, G. U. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.076 · Cited by 13
“Melanized DAergic neuronal cells in the substantia nigra pars compacta (SNc) and their projections to the striatum progressively degenerate in PD (Hirsch et al., 1988).”
BackgroundObata, T., Takahashi, S., Kashiwagi, Y., et al. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.005 · Cited by 13
“The cytotoxic ydroxyl radical (•OH) is involved in dopamine (DA) neurotoxic- ty caused by MPTP (Chiueh et al., 1993; Hirsch et al., 1988; Youdim t al., 1989).”
BackgroundSelf-Amplification of Nigral Degeneration in Parkinson's Disease: A Hypothesis
Ionov, I. D. (2008) · International Journal of Neuroscience · doi:10.1080/00207450802330561 · Cited by 15
Giovanni, G. D., Chagraoui, A., Puginier, E., Galati, S., & Deurwaerdère, P. D. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.014 · Cited by 13
Phenotype, Compartmental Organization and Differential Vulnerability of Nigral Dopaminergic Neurons
González‐Hernández, T., Afonso‐Oramas, D., & Cruz‐Muros, I. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_2 · Cited by 16
“(Fallon and Loughlin 1982; Heimer 2003; Joel and Weiner 2000) and the degeneration pattern in PD (Bernheimer et al. 1973; Damier et al. 1999b; Hirsch et al. 1988) and in animal models of PD (Burns et al.”
BackgroundPapapetropoulos, S. (2006) · Journal of Neuropsychiatry · doi:10.1176/jnp.2006.18.2.149 · Cited by 13
Znaidi, R., Massiani-Beaudoin, O., Mailly, P., Monnet, H., Bonnifet, T., The Brainbank Neuro-CEB Neuropathology Network, Joshi, R. L., & Fuchs, J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149579 · Cited by 14
“Human dopaminergic neurons are particularly vulnerable to neuro-degeneration observed in PD (Hirsch et al., 1988), express ORF1p more abundantly than surrounding neurons and their degeneration can be driven by LINE-1 expression in mice (Blaudin de Th ´ e et al., 2018).”
Hypoxia, Acidification and Inflammation: Partners in Crime in Parkinson’s Disease Pathogenesis?
Burtscher, J., & Millet, G. P. (2021) · Immuno · doi:10.3390/immuno1020006 · Cited by 15
“The second most common neurodegenerative disease, Parkinson’s Disease (PD), is characterized by the degeneration of dopaminergic (especially neuromelanin-containing [1]) neurons of the substantia nigra pars compacta that elicits the characteristic motor-symptoms, including bradykinesia, tremor and rigidity [2].”
BackgroundHattori, N., Kogo, Y., Koebis, M., Ishida, T., Suzuki, I., Tsuboi, Y., & Nomoto, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.752632 · Cited by 14
“In patients with PD, neurological deficits in dopamine production have been observed not only within the substantia nigra but also in the ventral tegmental area (VTA) of the brain (44, 45).”
BackgroundIonic Covalent Organosilicon Polymer Nanosheet for Selective and Sensitive Detection of Dopamine
Chai, R., Zhang, X., Zhao, Z., et al. (2023) · ACS Materials Letters · doi:10.1021/acsmaterialslett.3c00082 · Cited by 12
Effects of Hypericum perforatum on turning behavior in an animal model of Parkinson's disease
Vecchia, D. D., Schamne, M. G., Ferro, M. M., et al. (2015) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502015000100012 · Cited by 12
“Parkinson’s disease (PD) is a debilitating disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (Hirsch et al., 1988, 2005).”
Cell Based Therapies in Parkinson’s Disease
Behari, M., & Singhal, K. K. (2011) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.1118209 · Cited by 12
Bindhu, J., Das, A., & Sakthivel, K. M. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03188-7 · Cited by 12
Toward Generating Subtype-Specific Mesencephalic Dopaminergic Neurons in vitro
Cardoso, T., & Lévesque, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00443 · Cited by 14
DOPAMINE MERCAPTURATE CAN AUGMENT DOPAMINERGIC NEURODEGENERATION*
Montine, T. J., Amarnath, V., Picklo, M. J., Sidell, K. R., Zhang, J., & Graham, D. G. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102339 · Cited by 12
Kongros, K. (2012) · Journal of Medicinal Plants Research · doi:10.5897/jmpr11.1406 · Cited by 12
“(Hirsch et al., 1988; Olanow and Tatton, 1999).”
Hernández, R. A., Matas, M. J. S. D. L., Arriagada, C., Barcia, C., Caviedes, P. A., Herrero, M. T., & Segura‐Aguilar, J. (2003) · Neurotoxicity Research · doi:10.1007/bf03033169 · Cited by 12
“In PD, neuromelanin-containing neurons are more susceptible to neuronal cell death (Mann and Yates, 1983, Marsden, 1983; Hirsch et al., 1988) and MPTP-treated animals show a correlation between melanized neurons and age, and also with respect to vulnerability to degeneration (Herrero et al.,…”
BackgroundYoudim, M. B. H., & Ben‐Shachar, D. (1990) · New vistas in drug research · doi:10.1007/978-3-7091-9098-2_13 · Cited by 12
Dumas, S., Horellou, P., Helin, C., & Mallet, J. J. (1992) · Journal of Chemical Neuroanatomy · doi:10.1016/0891-0618(92)90030-t · Cited by 12
Obata, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00450-1 · Cited by 12
Lipids in the Treatment of Neurodegenerative Diseases
Lange, K. W. (2020) · Wiley eBooks · doi:10.1002/047167849x.bio118 · Cited by 12
Moreno, L. O., Bagüés, A., Martínez, V., & Abalo, R. (2023) · Nutrients · doi:10.3390/nu15122775 · Cited by 11
“PD is well known to be characterized by the irreversible loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and their corresponding axon terminals in the striatum [9].”
BackgroundYao, Y., Ji, Z., Lu, Z., Liu, X., Wang, Y., Liu, T., Zou, P., Dai, X., Wang, X., Ding, F., et al. (2019) · Microchimica Acta · doi:10.1007/s00604-019-3907-6 · Cited by 11
Astrocytes, a Promising Opportunity to Control the Progress of Parkinson’s Disease
Sánchez, A., Moráles, I., Rodriguez‐Sabate, C., Solé-Sabater, M., & Rodríguez, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101341 · Cited by 14
Helf, C., Kober, M., Markert, F., Lanto, J., Overhoff, L., Badstübner-Meeske, K., Storch, A., & Fauser, M. (2023) · Neuroreport · doi:10.1097/wnr.0000000000001917 · Cited by 11
Koyappayil, A., & Berchmans, S. (2016) · Journal of Solid State Electrochemistry · doi:10.1007/s10008-016-3482-2 · Cited by 11
Neurochemistry of Parkinson's disease
Rao, J. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83007-7 · Cited by 17
“The melanized cells degenerate more than the non-melanized cells (Hirsch et al., 1988); accordingly, loss of neurons in VTA in PD is less severe than in SNpc (Tong et al.”
BackgroundInfluentialGremlin is a novel VTA derived neuroprotective factor for dopamine neurons
Phani, S., Jablonski, M., Pelta-Heller, J., Cai, J., & Iacovitti, L. (2013) · Brain Research · doi:10.1016/j.brainres.2013.01.017 · Cited by 12
Analysis of organelles within the nervous system: impact on brain and organelle functions
Tribl, F., Meyer, H. E., & Marcus, K. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.333 · Cited by 12
Hunting genes in Parkinson’s disease from the roots
Muthane, U. B., Jain, S. K., & Gururaj, G. (2001) · Medical Hypotheses · doi:10.1054/mehy.2001.1289 · Cited by 11
Fungal melanins and their potential applications: A Review
Castillo, S. N. S., Peña, H. A. L., Díaz, R., Peña-Solis, K., Ponce‐Alquicira, E., Soriano-Santos, J., & Díaz-Godínez, G. (2023) · BioResources · doi:10.15376/biores.18.4.castillo · Cited by 11
“Neuromelanin is produced within human neurons through the oxidation of dopamine, norepinephrine, and catecholamines (Hirsch et al .”
BackgroundmicroRNA‐221 rescues the loss of dopaminergic neurons in a mouse model of Parkinson's disease
Yao, Y., Zhao, Z., Zhang, F., Miao, N., Wang, N., Xu, X., & Yang, C. (2023) · Brain and Behavior · doi:10.1002/brb3.2921 · Cited by 14
Aging, Parkinson’s Disease, and Models: What Are the Challenges?
Bellantuono, I., Mortiboys, H., Rocha, E. M., Chamoli, M., Chinta, S. J., Andersen, J. K., Wallis, R., Bézard, E., Goldberg, M., Greenamyre, T., et al. (2023) · doi:10.59368/agingbio.20230010 · Cited by 16
Breathing in Parkinsonism in the Rat
Białkowska, M., Boguszewski, P. M., & Pokorski, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/5584_2015_177 · Cited by 10
Machado, V., Gilsbach, R., Das, R., Schober, A., Bogatyreva, L., Hauschke, D., KRIEGLSTEIN, K. G., Unsicker, K., & Spittau, B. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2406-x · Cited by 12
Sympathetic nervous activity and hemoglobin levels in de novo Parkinson’s disease
Umehara, T., Oka, H., Nakahara, A., Shiraishi, T., Sato, T., Matsuno, H., Komatsu, T., Omoto, S., Murakami, H., & Iguchi, Y. (2020) · Clinical Autonomic Research · doi:10.1007/s10286-020-00668-3 · Cited by 10
Hayashi, J., Ton, J., Negi, S., Stephens, D. E. K. M., Pountney, D. L., Preiß, T., & Carver, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073700 · Cited by 12
“Although the accumulation of neuromelanin progressively increases with age, in PD, there is a direct correlation between the amount of neuromelanin present in the cell and its death [62,63].”
Zhang, Y.-Q., Zhang, M.-H., Ling, Z.-C., Wang, P.-G., & Jian, X.-Q. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.761720 · Cited by 8
“The main stimulation targets of this therapy are the internal globus pallidus (GPi) and the subthalamic nucleus (STN) (Hirsch et al., 1988; Aubry et al., 2003).”
BackgroundHow to improve neuroprotection in Parkinson's disease?
Hirsch, É. C. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70026-9 · Cited by 12
“We know that there is a very selective vulnerability of dopaminergic neurons, mostly in the substantia nigra and much less so in the VTA or in catecholaminergic cell group A8 [13].”
BackgroundIwabuchi, M., Hetu, M. M., & Tong, W. G. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.01.010 · Cited by 11
Blesa, J., & Vila, M. (2019) · Movement Disorders · doi:10.1002/mds.27618 · Cited by 10
Nobe, K., Ohata, H., & Momose, K. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)82454-9 · Cited by 10
Asakawa (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.4.144 · Cited by 9
Critical Role of Oxidatively Damaged DNA in Selective Noradrenergic Vulnerability
Zhan, Y., Raza, M. U., Yuan, L., & Zhu, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.036 · Cited by 9
The Proteome of Neuromelanin Granules in Dementia with Lewy Bodies
Wulf, M., Barkovits, K., Schork, K., Eisenacher, M., Riederer, P. F., Gerlach, M., Eggers, B., & Marcus, K. (2022) · Cells · doi:10.3390/cells11223538 · Cited by 10
“Since it is assumed that NMGs may be associated with the loss of dopaminergic neurons in the SN [7,23], we set out to compare the proteomic profile of NMGs and SNSurr.”
ResultFornstedt, B. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02718-2 · Cited by 10
“In parallel with the marked reductions in NM, it was observed that preferentially NM-con-taining catechol amine (CA) neurons degenerate (Mann and Yates 1983; Hirsch et al. 1988, 1989), which suggests that NM is involved in neurodegeneration and CA neuron death.”
Choi, Y. K., Feng, L., Jeong, W., & Kim, J. (2024) · Brain Informatics · doi:10.1186/s40708-024-00228-9 · Cited by 13
Dombrowski, P. A., de Carvalho, M. C., Miyoshi, E., Correia, D., Bortolanza, M., dos Santos, L. M., Lovato, E. C. W., Eckart, M. T., Schwarting, R. K. W., Brandão, M. L., et al. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.06.028 · Cited by 11
Klietz, M., Keber, U., Carlsson, T., Chiu, W., Höglinger, G. U., Weihe, E., Schäfer, M. K.-H., & Depboylu, C. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.017 · Cited by 11
Liu, H., Liu, C., Gu, Y., Li, C., Yan, X., Zhang, T., Lu, N., Zheng, B., Li, Y., Zhang, Z., et al. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.07.058 · Cited by 9
Monzani, E., Nicolis, S., Dell’Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie · doi:10.1002/ange.201811122 · Cited by 9
Histamine-4 Receptor: Emerging Target for the Treatment of Neurological Diseases
Shan, L., Martens, G. J. M., & Swaab, D. F. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_237 · Cited by 11
Generation and survival of midbrain dopaminergic neurons in weaver mice
Martí, J., Santa‐Cruz, M. C., Bayer, S. A., Ghetti, B. F., & Hervás, J. P. (2007) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2007.05.002 · Cited by 10
“SinceVTADAcells are also affected in Parkinsonian brains (Uhl et al., 1985; Hirsch et al., 1988; German et al., 1989) a similar analysis was performed in this region of the wv/wv group.”
MethodDepboylu, C., Klietz, M., Maurer, L., Oertel, W. H., Kobayashi, K., Weihe, E., Höglinger, G. U., & Schäfer, M. K.-H. (2014) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2014.10.003 · Cited by 11
The proteomic approach in Parkinson's disease
Fasano, M., Bergamasco, B., & Lopiano, L. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700264 · Cited by 10
“dence shows that the more pigmented neurons are the first ones to degenerate, suggesting thus that NM depletion does not occur at random [10]; conversely, it has been reported that the less pigmented ventral tier of SN is the first to Correspondence: Professor Mauro Fasano, Department of Structural and Functional Biol…”
BackgroundNeuromelanin-containing neurons are selectively vulnerable in parkinsonism
Langston, J. (1988) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(88)90248-9 · Cited by 9
Obata, T. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.03.071 · Cited by 9
Obata, T., Aomine, M., & Yamanaka, Y. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02238-6 · Cited by 9
Hedin, C. A. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90241-p · Cited by 9
Yamada, M., Groshan, K., Phung, C.-T., Yamada, M., Hisamitsu, T., & Richelson, E. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00139-8 · Cited by 10
Walker, R. H., Purohit, D. P., Good, P. F., Perl, D. P., & Brin, M. F. (2002) · Movement Disorders · doi:10.1002/mds.10098 · Cited by 9
Riederer, P. F., Sofic, E., Moll, G. H., Freyberger, A., Wichart, I., Gsell, W., Jellinger, K. A., Hebenstreit, G. F., & Youdim, M. B. H. (1990) · New vistas in drug research · doi:10.1007/978-3-7091-9098-2_21 · Cited by 9
Ahrens, J., Zaher, F., Rabin, R. A., Cassidy, C., & Palaniyappan, L. K. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105690 · Cited by 8
“…individuals with Parkinson ’ s disease, a condition characterized by SN dopamine neuronal death, the degree of dopamine neuron degeneration corresponds to the loss of neuromelanin-pigmented neurons, suggesting that neuromelanin serves as a proxy for midbrain dopaminergic tone (Hirsch et al., 1988).”
BackgroundAdeno-associated viral vectors for modeling Parkinson’s disease in non-human primates
Chocarro, J., & Lanciego, J. L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00896 · Cited by 8
“…in malignant melanocytes (Dean and Lee, 2021); (iii) the proven correlation between dopaminergic cell vulnerability and neuromelanin content (Hirsch et al., 1988, 1989; Kastner et al., 1992); and (iv) the fact that primates (human and non-human) are the only animal species with pigmented…”
Hovakimyan, M., Haas, S. J.-P., Schmitt, O., Gerber, B., Wree, A., & Andressen, C. (2008) · Cells Tissues Organs · doi:10.1159/000140680 · Cited by 8
Comprehensive Insight of Neurodegenerative Diseases and The Role of Neurotoxin Agents — Glutamate
Yap, H. M., Lye, K. L., & Tan, L. T. (2020) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000070 · Cited by 8
dos Santos, T. F. O., Santos, E. R., Bispo, J. M. M., Souza, M. F., de Gois, A. M., Lins, L. C. R. F., Silva, R. H., Ribeiro, A. M., Marchioro, M., & dos Santos, J. R. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111198 · Cited by 8
OXIDATIVE STRESS AND PARKINSON DISEASE
Nikolova, G. (2012) · Cited by 8
Unzeta, M., & Sanz, E. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00011-x · Cited by 8
“Most of these motor symptoms result from a depletion of striatal dopamine levels due to the degeneration of dopaminergicneurons in the nigrostriatal pathway (Hirsch et al., 1988; Dauer and Przedborski, 2003).”
BackgroundGrieb, B., Engler, G., Sharott, A., von Nicolai, C., Streichert, T., Papageorgiou, I. E., Schulte, A., Westphal, M., Lamszus, K., Engel, A. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091663 · Cited by 8
“This dissociation of dopaminergic degeneration is comparable to that seen in humans with PD, where the VTA is significantly less affected than the SN [62].”
ResultAcupuncture Treatment for Parkinson’s Disease
Asakawa, T., & Xia, Y. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3357-6_7 · Cited by 13
MPTP induced Parkinsonian syndrome: long term follow-up and neurophysiological study
ONOFRJ, M. C., & Ghilardi, M. F. (1990) · Neurological Sciences · doi:10.1007/bf02336564 · Cited by 8
Neuromelanin may Mediate Neurotoxicity via its Interaction with Redox Active Iron
Double, K. L., Zecca, L., Ben‐Shachar, D., Youdim, M. B. H., Riederer, P. F., & Gerlach, M. (2000) · Springer eBooks · doi:10.1007/978-1-4615-1269-1_20 · Cited by 8
Protective effect of histidine on MPP + -induced hydroxyl radical generation in rat striatum
Obata, T., & Inada, T. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01225-6 · Cited by 8
Drouin‐Ouellet, J., & Barker, R. (2012) · Stem Cells International · doi:10.1155/2012/926147 · Cited by 9
“Ventral midbrain dopaminergic neurons— especially those found in the substantia nigra—are those most vulnerable to degeneration in PD [27, 28], and it is known that these A9 nigral dopaminergic neurons are needed in cell transplants to restore function in animal models of PD [12, 29–31].”
BackgroundChesselet, M. (2000) · Elsevier eBooks · doi:10.1016/b978-012692545-6/50009-x · Cited by 9
Reduction of 13-Hydroperoxy-9,11-octadecadienoic Acid by Dopamine-Melanin
ȩ, K. S., Zajdel, A., Swierczek-Zieba, G., Wilczok, A., & Wilczok, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7678 · Cited by 9
Samancı, B., Tan, S. K. H., Michielse, S., Kuijf, M. L., & Temel, Y. (2024) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2024.102392 · Cited by 13
Mondal, R., Mukherjee, N., & Ahmed, S. F. (2024) · ACS Applied Electronic Materials · doi:10.1021/acsaelm.4c00947 · Cited by 6
Kariya, S., Hirano, M., Takahashi, N., Furiya, Y., & Ueno, S. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.02.005 · Cited by 7
“Clinical symptoms of PD appear when patients have lost approximately 50–80% of dopaminergic neurons in the substania nigra pars compacta [2].”
BackgroundDepboylu, C. (2014) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2014.02.001 · Cited by 9
Kang, J. M., Jung, J., Kim, H., Lim, H., Jang, S., & Oh, S. (2008) · Archives of Pharmacal Research · doi:10.1007/s12272-001-1275-5 · Cited by 7
“Immunohistochemistry was performed as described previously (Hirsch et al., 1988) on free-floating cryomicrotome-cut sections (40 µm thick) that encompassed the entire striatum (ST) and substantia nigra (SN).”
BackgroundMethodInfluentialKimura, K., Inoue, K., Kuroiwa, Y., Tanaka, F., & Takada, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166861 · Cited by 8
Etiology and pathogenesis of Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00005-6 · Cited by 9
Kainic acid lesion-induced nigral neuronal death
Foster, J. A., Bezin, L., Groc, L., Christopherson, P. L., & Levine, R. A. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(03)00040-1 · Cited by 8
Mahmoudian, M. R., Basirun, W. J., & Alias, Y. B. (2017) · Journal of Alloys and Compounds · doi:10.1016/j.jallcom.2016.12.439 · Cited by 7
Biological Role of Neuromelanin in the Human Brain and Its Importance in Parkinson's Disease
Double, K. L., Maruyama, W., Naoi, M., Gerlach, M., & Riederer, P. F. (2011) · Wiley eBooks · doi:10.1002/9783527636150.ch8 · Cited by 7
Jacobs, F. M. J., Smits, S. M., Hornman, K. J. M., Burbach, J. P. H., & Smidt, M. P. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.113233 · Cited by 8
“Interestingly, this mdDA neuronal subgroup is defined as the selectively vulnerable group compromised in PD (Hirsch et al. 1988) and is known to be very sensitive to neurotoxins such as MPTP and 6-OHDA (Ungerstedt et al.”
BackgroundNeuropsychological correlates of l-deprenyl therapy in idiopathic parkinsonism
Finali, G., Piccirilli, M., & Piccinin, G. L. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90028-0 · Cited by 7
Obata, T., & Yamanaka, Y. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01421-x · Cited by 7
Alushaj, E., Kuurstra, A. B., Menon, R. S., Ganjavi, H., Morava, A., Sharma, M., Kashgari, A., Barr, J., Reisman, W. M., KHAN, A. R., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00916-1 · Cited by 8
Waldvogel (1999) · doi:10.1002/1531-8249(199907)46:1
Self-citation
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.